Showing results (801-810 of 847) with videos related to

Sort By:
Pageof 85
Frontiers in Digital Health|June 15, 2026
Best practices and challenges in executing large scale pilots for eHealth deployment and managing innovation: the GATEKEEPER experienceDavide Piaggio, Jordi de Batlle, Alba M Gallego Montejo, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
The Lancet. Oncology|December 17, 2022
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trialRoberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Leukemia|April 17, 2013
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsY-T Tai, Y Landesman, C Acharya, et al.
Cancer Medicine|April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experienceAnna Furlan, Michele Cea, Laura Pavan, et al.
BMC Pediatrics|November 10, 2023
The Bern Birth Cohort (BeBiCo) to study the development of the infant intestinal microbiota in a high-resource setting in Switzerland: rationale, design, and methodsLuca Cecchini, Colette Barmaz, Maria José Coloma Cea, et al.
Nature Ecology & Evolution|December 18, 2019
Positive associations among rare species and their persistence in ecological assemblagesJoaquín Calatayud, Enrique Andivia, Adrián Escudero, et al.
Blood Neoplasia|January 2, 2026
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment responseAnna Maria Corsale, Mojtaba Shekarkar Azgomi, Emilia Gigliotta, et al.
Blood Advances|December 11, 2024
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myelomaDebora Soncini, Pamela Becherini, Francesco Ladisa, et al.
Blood|June 13, 2012
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaYu-Tzu Tai, Betty Y Chang, Sun-Young Kong, et al.
Pageof 85